25,729 articles
Alectinib
Alectinib (Alecensa) is an oral ALK and RET tyrosine kinase inhibitor for ALK-positive NSCLC, first approved in Japan in 2014; superior to crizotinib in ALEX and FDA-approved for adjuvant use in 2024.
Alefacept
Alefacept (Amevive) is an LFA-3/IgG1 fusion protein that binds CD2 to deplete memory T cells; first US-approved psoriasis biologic (2003), 15 mg IM weekly for 12 weeks, later discontinued by its manufacturer.
Aleglitazar
Aleglitazar: Roche's dual PPARα/γ agonist (C24H23NO5S) for type 2 diabetes; improved HbA1c and lipids but AleCardio phase III (7,226 patients) stopped July 2013 for futility and renal, bleeding, heart-failure signals.
Aleida Guevara
Aleida Guevara March, eldest daughter of Che Guevara and Aleida March, is a Cuban pediatrician, Communist Party member, and ICAP representative who defends Cuba's government and manages her father's image legacy.
Alemtuzumab
Alemtuzumab (Campath, MabCampath, Lemtrada) is a humanized anti-CD52 monoclonal antibody, FDA-approved in 2001 for fludarabine-failed B-cell CLL, fully approved in 2007 after CAM307, withdrawn in the EU in 2012, and repurposed as Lemtrada for relapsing multiple sclerosis.
Alemtuzumab therapy
Alemtuzumab therapy is treatment with a monoclonal antibody that depletes lymphocytes, used mainly for relapsing multiple sclerosis and formerly for B-cell chronic lymphocytic leukemia, first approved in 2001.
Alendronic acid
Alendronic acid (alendronate, Fosamax) is an oral amino-bisphosphonate inhibiting farnesyl pyrophosphate synthase, used for osteoporosis, glucocorticoid-induced osteoporosis, and Paget's disease; 70 mg weekly dosing, FDA-approved 1995.
Aleniglipron
Aleniglipron (GSBR-1290) is Structure Therapeutics' oral, once-daily, non-peptide small-molecule GLP-1 receptor agonist for obesity; phase 2 ACCESS trials showed up to 16.3% placebo-adjusted weight loss at 44 weeks, with phase 3 planned for 2026.
Alex Azar
Alex Azar (born 1967) is an American lawyer and former Eli Lilly executive who was the 24th US Secretary of Health and Human Services, 2018-2021, under Trump, after serving as HHS general counsel and deputy secretary under Bush.
Alex Gorsky
Alex Gorsky, American executive, West Point graduate and Army captain, was Chairman and CEO of Johnson & Johnson 2012-2021 and Executive Chairman 2022; later director at Apple, IBM, and JPMorgan Chase.
Alex H. Krist
Alex H. Krist is an American family physician and researcher at Virginia Commonwealth University who chaired the U.S. Preventive Services Task Force from 2020 to 2021.
Alex Zhavoronkov
Alex Zhavoronkov (Aleksandrs Zavoronkovs), Latvian-born Canadian scientist, founder and CEO of Insilico Medicine, the AI drug discovery company behind rentosertib, the first AI-discovered, AI-designed drug in human trials, listed on HKEX in December 2025.
Alexander disease
Alexander disease, a rare GFAP-gene leukodystrophy and primary astrocyte disorder marked by Rosenthal fibers, infantile to adult forms, supportive care, and the 2026 FDA approval of zilganersen.
Alfacalcidol
Alfacalcidol (1α-hydroxycholecalciferol) is a synthetic vitamin D3 analog and calcitriol prodrug that needs no kidney activation, used for chronic kidney disease bone disease, secondary hyperparathyroidism, hypoparathyroidism, and osteoporosis.
Alfentanil
Alfentanil (Rapifen) is a short-acting synthetic opioid analgesic derived from fentanyl and given intravenously during anesthesia. Synthesized by Janssen in 1976, it is a DEA Schedule II controlled substance.
Alferminogene tadenovec
Alferminogene tadenovec (Generx, Ad5FGF-4, AGT-MI) is an unapproved adenovirus serotype 5 gene therapy expressing FGF-4 for refractory angina; AGENT-3/4 failed on placebo response, later phase 3 trials incomplete.
Alfimeprase
Alfimeprase, a recombinant truncated fibrolase from Southern copperhead venom, is a direct-acting fibrinolytic metalloprotease developed by Amgen and Nuvelo; phase III NAPA-2 and SONOMA-2 trials failed, and development was discontinued in 2008.
Alfosbuvir
Alfosbuvir (奥磷布韦, trade name Shennuodi) is a Chinese Class-1 NS5B nucleotide inhibitor for chronic HCV genotypes 1, 2, 3, 6, approved by NMPA in May 2023 for use with daclatasvir, achieving 98.2% SVR12 in phase 3.
Alfred O. Berg
Alfred O. Berg is an American family physician and prevention researcher, professor and chair of family medicine at the University of Washington, who chaired the U.S. Preventive Services Task Force.
Alfred P. Fishman
Alfred P. Fishman was an American pulmonary physician-scientist at the University of Pennsylvania who organized the National Registry on Primary Pulmonary Hypertension and wrote a standard textbook.
Alfred Washington Adson
Alfred Washington Adson (1887–1951) was an American neurosurgeon who founded Mayo Clinic's first neurosurgical department, led it from 1921 to 1946, and described the Adson maneuver for thoracic outlet syndrome.
Alfredo Bowman
Alfredo Darrington Bowman, aka Dr. Sebi (1933–2016), Honduran-born self-educated herbalist of Garifuna descent who created the African Bio-Mineral Balance alkaline diet, was acquitted in a 1988 New York unlicensed-medicine trial, and died in Honduran police custody; no scientific evidence supports his cure claims.
ALFSG study
The ALFSG study was a prospective registry of acute liver failure run by the Acute Liver Failure Study Group across 33 sites from 1998 to 2019.
ALFUSABA study
ALFUSABA (NCT05247359), a completed cross-sectional observational study by University Rovira i Virgili profiling neuromuscular jump-landing deficits in 104 Catalan basketball players aged 12 to 14, measuring ankle stability, dynamic knee valgus, core stability, and limb symmetry.
Alfuzosin
Alfuzosin (Uroxatral, Xatral) is a quinazoline alpha-1 adrenergic antagonist for benign prostatic hyperplasia symptoms; 10 mg once-daily extended-release tablet, FDA approved 2003, no dose titration, not for hypertension.
ALG-pathway congenital disorders of glycosylation
ALG-pathway congenital disorders of glycosylation are inherited metabolic diseases in which defective ALG-family genes disrupt assembly of lipid-linked oligosaccharides in the endoplasmic reticulum, causing type I CDG; ALG6-CDG is the most common subtype.
ALG1-CDG
ALG1-CDG (formerly CDG-Ik, OMIM 608540) is a rare autosomal recessive N-glycosylation disorder caused by biallelic ALG1 variants on 16p13, impairing the first mannose addition step, with severe neurological multisystem disease and a diagnostic xeno-tetrasaccharide biomarker.
ALG11-CDG
ALG11-CDG (CDG-Ip) is a rare autosomal recessive N-glycosylation disorder caused by ALG11 mutations, causing epilepsy, developmental disability, microcephaly, and sensorineural deafness, with no specific treatment.
ALG13-CDG
ALG13-CDG (CDG type Is, EIEE36) is a rare X-linked congenital disorder of glycosylation caused by ALG13 gene variants, presenting in infancy with epileptic spasms, hypotonia, and developmental delay; transferrin tests are usually normal, so genetic sequencing confirms it.
ALG2-CDG
ALG2-CDG (CDG-Ii, CDG1I, mannosyltransferase 2 deficiency) is an ultra-rare autosomal recessive congenital disorder of glycosylation from ALG2 loss-of-function variants, causing infantile spasms, iris coloboma, cataract, developmental delay, and coagulopathy.